Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M50.4Revenue (TTM) $M--Net Margin (%)--Altman Z-Score-12.3
Enterprise Value $M32.9EPS (TTM) $-0.9Operating Margin %--Piotroski F-Score2
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book7.310-y EBITDA Growth Rate %-5.8Quick Ratio5.0Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %5.0Current Ratio5.0Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-98.9Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-174.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M29.3ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with GALT

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GALTGeorge Soros 2014-06-30 Sold Out -0.01%$10.23 - $14.81
($12.43)
$ 1.72-86%Sold Out0
GALTGeorge Soros 2014-03-31 Buy 0.01%$8.025 - $18.3
($14.02)
$ 1.72-88%New holding48,200
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GALT is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


GALT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CZIRR JAMES CDirector 2016-04-20Sell44,312$1.672.99view
10X Fund, L.P.10% Owner 2016-04-20Sell44,312$1.672.99view
Greenberg ArthurDirector 2016-01-05Buy1,666$1.720view
AMELIO GILBERT FDirector 2015-11-30Sell100$2.1-18.1view
TRABER PETER GPresident & CEO 2015-08-12Buy2,000$2-14view
TRABER PETER GPresident & CEO 2015-06-01Buy4,000$2.53-32.02view
FREEMAN KEVIN DDirector 2015-06-01Buy2,083$2.7-36.3view
AMELIO GILBERT FDirector 2014-12-15Sell110$3.69-53.39view
Greenberg ArthurDirector 2014-08-19Buy1,000$4.56-62.28view
FREEMAN KEVIN DDirector 2014-08-15Buy1,000$4.7-63.4view

Press Releases about GALT :

Quarterly/Annual Reports about GALT:

News about GALT:

Articles On GuruFocus.com
No related article found.

More From Other Websites
Galectin Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference Aug 31 2016
Galectin Therapeutics Announces Results From 12-Week Extension of Phase 2a Psoriasis Clinical Trial Aug 25 2016
Galectin Therapeutics Announces Results From 12-Week Extension of Phase 2a Psoriasis Clinical Trial Aug 25 2016
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Aug 25 2016
GALECTIN THERAPEUTICS INC Financials Aug 17 2016
Galectin Therapeutics Reports Second Quarter 2016 Financial Results and Provides Business Update Aug 09 2016
Galectin Therapeutics Reports Second Quarter 2016 Financial Results and Provides Business Update Aug 09 2016
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 09 2016
GALECTIN THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report Aug 09 2016
Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02... Aug 02 2016
Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02... Aug 02 2016
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Aug 02 2016
Galectin Therapeutics (GALT) Jumps: Stock Rises 17.1% Aug 02 2016
Peter G. Traber, M.D., CEO and CMO of Galectin Therapeutics, to Speak on the Medical Applications of... Jul 13 2016
Peter G. Traber, M.D., CEO and CMO of Galectin Therapeutics, to Speak on the Medical Applications of... Jul 13 2016
Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in... Jul 12 2016
Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in... Jul 12 2016
Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in... Jul 12 2016
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jun 20 2016
Galectin Therapeutics Announces Positive Preclinical Results on the Role of Galectin-3 in Mediating... Jun 02 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)